| Legal status | Investigational |
|---|---|
| Cas number | 477775-14-7 |
| Pubchem | 9804984 |
| Drugbank | DB18038 |
| Chemspiderid | 7980744 |
| Unii | RC2V4W0EYC |
| Kegg | D13133 |
| Chembl | 189568 |
| Synonyms | VP-01 |
| Iupac name | butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate |
| C | 23 |
| H | 29 |
| N | 3 |
| O | 4 |
| S | 2 |
| Smiles | CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3 |
| Stdinchi | 1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27) |
| Stdinchikey | XTEOJPUYZWEXFI-UHFFFAOYSA-N |
Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.[1] It is an angiotensin II receptor type 2 agonist.[2] The drug was discovered and developed by Professor Anders Hallberg and colleagues at the University of Uppsala. As at late 2024 it was on large scale trials for treatment of lung fibrosis following successful small-scale trials. Development is supported by investment from Sanofi.[3]
References
- ^ "Buloxibutid - Vicore Pharma". AdisInsight. Springer Nature Switzerland AG.
- ^ Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, Dalsgaard CJ (February 2024). "Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist". Clinical and Translational Science. 17 (2). doi:10.1111/cts.13735. PMC 10859786. PMID 38344891
- ^ Basic research led to drug candidates for fatal lung disease by Åsa Malmberg, Uppsala University news, 18 November 2024 https://www.uu.se/en/news/2024/2024-11-18-basic-research-led-to-drug-candidates-for-fatal-lung-disease